X

You are using an unsupported browser. Please upgrade your version in order to view the pharmaprix.ca site.

Unanswered questions about NAbs

Featuring content from MediResource Inc.

Knowledge about NAbs has come a long way in recent years, but there are still some unanswered questions about them and what they mean for MS therapy. Areas that require more research include:

  • developing better and more consistent ways of measuring NAbs so that results are consistent between laboratories in different locations
  • learning more about which factors increase the risk of NAbs to help predict who may develop NAbs
  • understanding exactly how NAbs are produced and how they affect MS medications
  • determining the effect of NAbs on the progression of MS in people taking disease-modifying medications (such as interferon beta)
  • understanding why NAbs affect medication response for some, but not all, people
  • determining why NAbs go away in some cases and how this influences the effectiveness of disease-modifying medications
  • finding a way to prevent the development of NAbs, to get rid of NAbs once they appear, or to stop them from affecting MS medications
  • learning how NAbs affect MS therapy over the long term (several years)

NAbs are an active area of MS research. Ongoing research should help to answer these and other questions. It will also help us gain a better understanding of why and how NAbs affect MS therapy and what can be done about them.

All material copyright MediResource Inc. 1996 – 2020. Terms and conditions of use. The contents herein are for informational purposes only. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Source: www.medbroadcast.com/healthfeature/gethealthfeature/MS-The-Role-of-NAbs